1. Home
  2. DVAX vs NABL Comparison

DVAX vs NABL Comparison

Compare DVAX & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • NABL
  • Stock Information
  • Founded
  • DVAX 1996
  • NABL 2000
  • Country
  • DVAX United States
  • NABL United States
  • Employees
  • DVAX N/A
  • NABL N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • NABL Computer Software: Prepackaged Software
  • Sector
  • DVAX Health Care
  • NABL Technology
  • Exchange
  • DVAX Nasdaq
  • NABL Nasdaq
  • Market Cap
  • DVAX 1.7B
  • NABL 1.8B
  • IPO Year
  • DVAX 2004
  • NABL N/A
  • Fundamental
  • Price
  • DVAX $12.45
  • NABL $9.24
  • Analyst Decision
  • DVAX Buy
  • NABL Strong Buy
  • Analyst Count
  • DVAX 2
  • NABL 2
  • Target Price
  • DVAX $23.00
  • NABL $15.75
  • AVG Volume (30 Days)
  • DVAX 1.8M
  • NABL 765.7K
  • Earning Date
  • DVAX 02-20-2025
  • NABL 02-20-2025
  • Dividend Yield
  • DVAX N/A
  • NABL N/A
  • EPS Growth
  • DVAX N/A
  • NABL 72.50
  • EPS
  • DVAX 0.15
  • NABL 0.20
  • Revenue
  • DVAX $260,810,000.00
  • NABL $458,053,000.00
  • Revenue This Year
  • DVAX $21.64
  • NABL $12.07
  • Revenue Next Year
  • DVAX $19.81
  • NABL $10.50
  • P/E Ratio
  • DVAX $82.38
  • NABL $46.24
  • Revenue Growth
  • DVAX N/A
  • NABL 11.93
  • 52 Week Low
  • DVAX $9.74
  • NABL $8.92
  • 52 Week High
  • DVAX $14.30
  • NABL $15.49
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 41.74
  • NABL 35.65
  • Support Level
  • DVAX $12.27
  • NABL $8.92
  • Resistance Level
  • DVAX $12.74
  • NABL $9.72
  • Average True Range (ATR)
  • DVAX 0.35
  • NABL 0.22
  • MACD
  • DVAX -0.06
  • NABL 0.03
  • Stochastic Oscillator
  • DVAX 37.39
  • NABL 40.37

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. it also has a presence in the United Kingdom and all other International regions.

Share on Social Networks: